a; Johannes C. Kelder, MDa; Maarten Jan Suttorp, MD, PhDa; Freek W.A. Verheugt, MD, PhDb; H.W.Thijs Plokker, MD, PhDa">
Journal Home
Search for

Volume 145, Issue 1, Pages 58-65 (January 2003)


View previous. 10 of 30 View next.

A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: Results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS)

Jurriën M. ten Berg, MDa, Johannes C. Kelder, MDa, Maarten Jan Suttorp, MD, PhDa, Freek W.A. Verheugt, MD, PhDb, H.W.Thijs Plokker, MD, PhDa

Abstract 

Background Thrombus formation during coronary angioplasty may play a role in the restenosis process.Methods The effect of pretreatment with coumarins on 6-month angiographic outcome was studied. In addition, the effect of “optimal” anticoagulation, defined as an international normalized ratio >70% of the follow-up time in the target range, was studied. A total of 261 patients were assigned to aspirin alone (ASA group) and 270 patients to aspirin plus coumarins started 1 week before the procedure (coumarin group).Results The mean international normalized ratio was 2.7 ± 1.2 at the start of the procedure and 3.1 ± 0.5 during follow up. Quantitative coronary analysis was performed on 301 lesions in the ASA group and of 297 lesions in the coumarin group. At 6 months, the minimal luminal diameter was similar in the ASA and coumarin groups. Optimal anticoagulation, however, was an independent predictor of a larger minimal luminal diameter at follow up (P = .01).Conclusion Overall, coumarins do not improve angiographic outcome 6 months after coronary angioplasty. (Am Heart J 2003;145:58-65.)

No full text is available. To read the body of this article, please view the PDF online.

From the aDepartment of Interventional Cardiology, St Antonius Hospital, Nieuwegein, and the bDepartment of Cardiology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

 Supported by a grant (94138) from the Netherlands Heart Foundation.

PII: S0002-8703(02)94772-1

doi:10.1067/mhj.2003.63


View previous. 10 of 30 View next.